EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

inositol niacinate
3-pyridinecarboxylic acid, 1,2,3,4,5,6-cyclohexanehexayl ester

Supplier Sponsors

Name:[2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl] pyridine-3-carboxylate
CAS Number: 6556-11-2Picture of molecule3D/inchi
Other(deleted CASRN):14154-33-7
ECHA EINECS - REACH Pre-Reg:229-485-9
FDA UNII: A99MK953KZ
Nikkaji Web:J3.420G
Beilstein Number:0077649
MDL:MFCD00006387
XlogP3-AA:3.30 (est)
Molecular Weight:810.73350000
Formula:C42 H30 N6 O12
BioActivity Summary:listing
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:dietary supplements
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Perfumer and Flavorist:Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Appearance:white crystalline powder (est)
Assay: 98.00 to 100.00
Food Chemicals Codex Listed: No
Melting Point: 254.00 to 255.00 °C. @ 760.00 mm Hg
Boiling Point: 897.00 to 898.00 °C. @ 760.00 mm Hg (est)
Flash Point: 925.00 °F. TCC ( 496.30 °C. ) (est)
logP (o/w): 3.945 (est)
Soluble in:
 acetone
 alcohol
 water, 0.2853 mg/L @ 25 °C (est)
Insoluble in:
 water
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
A.M.G.L.T.
Inositol Niacinate
AIDP
Inositol Nicotinate Inositol Niacinate 98%-101%
BBFY Industrial
Inositol Niacinate
BOC Sciences
For experimental / research use only.
Inositol nicotinate
Charkit Chemical
INOSITOL HEXANICOTINATE
Indis NV
For experimental / research use only.
Inositol Niacinate
Maypro Industries
Inositol Nicotinate
Santa Cruz Biotechnology
For experimental / research use only.
myo-Inositol hexanicotinate ≥98%
Sigma-Aldrich: Sigma
For experimental / research use only.
myo-Inositol hexanicotinate
sds
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
oral-rat LD50 > 20000 mg/kg
Oyo Yakuri. Pharmacometrics. Vol. 14(5), Pg. 741, 1977.

intravenous-rat LD50 268 mg/kg
Drugs in Japan Vol. 6, Pg. 77, 1982.

intraperitoneal-rat LD50 > 10000 mg/kg
Oyo Yakuri. Pharmacometrics. Vol. 14(5), Pg. 741, 1977.

oral-mouse LD50 > 30000 mg/kg
Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 149, 1973.

intravenous-mouse LD50 345 mg/kg
Drugs in Japan Vol. 6, Pg. 77, 1982.

intraperitoneal-mouse LD50 6400 mg/kg
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 149, 1973.

Dermal Toxicity:
subcutaneous-rat LD50 1180 mg/kg
Drugs in Japan Vol. 6, Pg. 77, 1982.

subcutaneous-mouse LD50 > 5000 mg/kg
Oyo Yakuri. Pharmacometrics. Vol. 14(5), Pg. 741, 1977.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
dietary supplements
Recommendation for inositol niacinate usage levels up to:
 not for fragrance use.
 
Recommendation for inositol niacinate flavor usage levels up to:
 not for flavor use.
 
Safety References:
European Food Safety Authority (EFSA) reference(s):

Inositol hexanicotinate (inositol hexaniacinate) as a source of niacin (vitamin B3) added for nutritional purposes in food supplements
View page or View pdf

Scientific Opinion on the substantiation of a health claim related to the combination of artichoke leaf dry extract standardised in caffeoylquinic acids, monacolin K in red yeast rice, sugar-cane derived policosanols, OPC from French maritime pine bark, garlic dry extract standardised in allicin, d-a-tocopheryl hydrogen succinate, riboflavin and inositol hexanicotinate in Limicol® and reduction of blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation (EC) No 1924/2006
View page or View pdf

EPI System: View
Daily Med:search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :3720
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:2
[2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl] pyridine-3-carboxylate
Chemidplus:0006556112
RTECS:NM7535400 for cas# 6556-11-2
 
References:
 [2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl] pyridine-3-carboxylate
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):3720
Pubchem (sid):135264266
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):D01813
HMDB (The Human Metabolome Database):Search
Export Tariff Code:2933.39.4700
FDA Listing of Food Additive Status:View
ChemSpider:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
 cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate
 cyclohexane-1,2,3,4,5,6-hexayl hexapyridine-3-carboxylate
 hexanicotinoyl inositol
 inositol hexanicotinate
 inositol nicotinate
 inositol, hexanicotinate, myo-
 inositoli nicotinas
 mesonex
2,3,4,5,6-pentakis((3-pyridinylcarbonyl)oxy)cyclohexyl nicotinate
[2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl] pyridine-3-carboxylate
3-pyridinecarboxylic acid, 1,2,3,4,5,6-cyclohexanehexayl ester
 

Articles:

PubMed:Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
PubMed:Biotransformation and pharmacokinetics of inositol hexanicotinate in rats.
PubMed:Niacin: chemical forms, bioavailability, and health effects.
PubMed:A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
PubMed:Synthesis and antihyperlipidemic activity of acetylated derivative of ulvan from Ulva pertusa.
PubMed:Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection.
PubMed:Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products.
PubMed:Purported benefits of inositol niacinate.
PubMed:Antihyperlipidemic effects of different molecular weight sulfated polysaccharides from Ulva pertusa (Chlorophyta).
PubMed:Inositol hexaniacinate.
PubMed:The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial.
PubMed:Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial.
PubMed:A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
PubMed:Inositol nicotinate in intermittent claudication.
PubMed:Treatment of intermittent claudication with inositol nicotinate.
PubMed:A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication.
PubMed:[Use of derivative resolution for the spectrophotometric analysis of drug mixtures. I. Determination of inositol hexanicotinate and bamethan sulfate in tablets].
PubMed:[Experience with the medical treatment of chronic cerebrovascular insufficiency: bamethan and inositol nicotinate versus placebo].
PubMed:Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome.
PubMed:Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
PubMed:Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
PubMed:Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues.
PubMed:[Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial].
PubMed:A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion.
PubMed:[Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].
PubMed:[Clinical use of a thermal method for measuring peripheral blood flow according to A.M. Baptista (author's transl)].
PubMed:[Inositol hexanicotinate and its cholesteropenic effect].
PubMed:[Ulcers of the lower extremities. Treatment with inositol hexanicotinate].
PubMed:[Ocular changes experimentally induced in guinea pigs treated with an association of kallikrein and meso-inositol hexanicotinate].
PubMed:[On the fibrinolytic effect of the combination of kallikrein with meso-inositol hexanicotinate].
PubMed:The use of Hexanicotol (inositol niacinate) in peripheral vascular disease.
PubMed:[Research on skin temperature and internal temperature in subjects with obliterating arteriopathy. Action of the association of kallikrein and meso-inositol hexanicotinate].
PubMed:[Clinical considerations and functional data on the use of the association of kallikrein and meso-inositol hexanicotinate in the therapy of obliterating arteriopathy].
PubMed:[The association of kallikrein and inositol hexanicotinate in the therapy of peripheral obliterating arteriopathy].
PubMed:[Effect of meso-inositol hexanicotinate on arteriosclerosis].
PubMed:[FIRST EXPERIENCES ON THE THERAPEUTIC ACTIVITY OF M-INOSITOL HEXANICOTINATE AND KALLIKREIN IN PERIPHERAL VASCULAR DISEASES AND IN CORONARY DISEASE].
PubMed:[APROPOS OF THE GASTROINTESTINAL ABSORPTION OF INOSITOL HEXANICOTINATE].
PubMed:[PHARMACOLOGICAL EXPERIMENTS WITH A COMBINATION OF KALLIKREIN AND MESO-INOSITOL HEXANICOTINATE].
PubMed:[CLINICAL TESTING OF MESO-INOSITOL-HEXANICOTINATE].
PubMed:[CLINICAL TRIAL OF A NEW NICOTINIC ACID DERIVATIVE, MESO-INOSITOL-HEXANICOTINATE, IN NEUROPSYCHIATRY].
PubMed:[INOSITOL HEXANICOTINATE IN THE THERAPY OF ULCUS CRURIS].
PubMed:[Therapy of peripheral arteriopathies with a compound with a base of inositol hexanicotinate].
PubMed:Inositol niacinate as a peripheral vasodilator.
PubMed:[Apropos of the hypocholesterolemic effects of nicotinic acid. Experimental investigations of such a compound and of inositol hexanicotinate].
PubMed:Inositol hexanicotinate for improved nicotinic acid therapy. Preliminary report.
PubMed:Speripheral vascular disease in general practice. Some experiences with meso-inositol-hexanicotinate.
 
Notes:
None found
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy